RESUMO
The cytokine interleukin (IL)-11 has been shown to play a role in promoting fibrosis and cancer, including lung adenocarcinoma, garnering interest as an attractive target for therapeutic intervention. We used combinatorial methods to engineer an IL-11 variant that binds with higher affinity to the IL-11 receptor and stimulates enhanced receptor-mediated cell signaling. Introduction of two additional point mutations ablates IL-11 ligand/receptor association with the gp130 coreceptor signaling complex, resulting in a high-affinity receptor antagonist. Unlike wild-type IL-11, this engineered variant potently blocks IL-11-mediated cell signaling and slows tumor growth in a mouse model of lung cancer. Our approach highlights a strategy where native ligands can be engineered and exploited to create potent receptor antagonists.
RESUMO
Herein, a synthetic method was developed to prepare a series of tris(dialkylamino)sulfonium and sulfoxonium cations from sulfur monochloride. Alkaline stability studies of these two cation families in 2 M KOH/CD3OH solution at 80 °C revealed how degradation pathways change as a function of the oxidation state of the S center, as determined by 1H NMR spectroscopy. The sulfonium cations (+S(NR2)3) typically degrade by nucleophilic attack at the sulfur atom with loss of an amino group and a proton transfer reaction to produce sulfoxides, while the sulfoxoniums (+OâS(NR2)3) tend to degrade by loss of an R group to form sulfoximines. From the group of sulfoniums and sulfoxoniums explored in this work, the tris(piperidino)sulfoxonium cation was noted to have excellent alkaline stability. This sulfoxonium should be suitable for future examination as a tethered cation in anion-exchange membranes (AEMs), or as a phase-transfer catalyst in biphasic reactions.
